<DOC>
	<DOCNO>NCT00030680</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . PURPOSE : Phase II trial study effectiveness radiation therapy treat patient aggressive fibromatoses .</brief_summary>
	<brief_title>Radiation Therapy Treating Patients With Aggressive Fibromatoses</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy moderate-dose radiotherapy , term local control , patient aggressive fibromatoses . - Determine acute late side-effects regimen patient . OUTLINE : This multicenter study . Patients receive radiotherapy 5 day week 5.5 week total 56 Gy 28 fraction . Patients follow every 3 month 2 year every 6 month thereafter . PROJECTED ACCRUAL : A total 40 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Fibromatosis , Aggressive</mesh_term>
	<mesh_term>Fibroma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm aggressive fibromatoses arise site Primary , recurrent , progressive disease inoperable require major operation result large functional cosmetic deficit mutilation Progressive disease define least 20 % increase tumor size 2 MRI scan within 1 year prior therapy except radiotherapy OR Incompletely resect tumor gross residual disease suitable surgery Resected within past 3 month Lesions must suitable radiotherapy No bulky intraabdominal disease close relation small bowel Measurable disease PATIENT CHARACTERISTICS : Age : 16 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No condition would preclude study followup PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior chemotherapy allow No concurrent chemotherapy Endocrine therapy : Prior endocrine therapy allow No concurrent endocrine therapy Radiotherapy : See Disease Characteristics No prior radiotherapy indicator lesion Surgery : See Disease Characteristics Prior surgery allow Other : No prior isolate limb perfusion tumor necrosis factor No concurrent isolate limb perfusion tumor necrosis factor</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>desmoid tumor</keyword>
</DOC>